Bartogenic acid

Bartogenic acid 是一种可于玉蕊 (Barringtonia racemosa) 果实中发现的 NF-κB 抑制剂,能提高过氧化氢酶、超氧化物歧化酶 (SOD) 及谷胱甘肽水平,抑制脂质过氧化并下调炎症标志物表达,可用于卵巢癌、皮肤癌及炎症性疾病的相关研究。
产品编号: MS-P32474 CAS No.: 79355-89-8 分子式: C30H46O7 分子量: 518.68
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Bartogenic acid 是一种可于玉蕊 (Barringtonia racemosa) 果实中发现的 NF-κB 抑制剂,能提高过氧化氢酶、超氧化物歧化酶 (SOD) 及谷胱甘肽水平,抑制脂质过氧化并下调炎症标志物表达,可用于卵巢癌、皮肤癌及炎症性疾病的相关研究。

生物实验数据

生物活性 Bartogenic acid is an NF-κB inhibitor found in the fruit of Barringtonia racemosa that elevates catalase, superoxide dismutase (SOD), and glutathione levels, inhibits lipid peroxidation, and downregulates inflammatory marker expression, and it can be used in research related to ovarian cancer, skin cancer, and inflammatory diseases.
IC50 & Target

NF-κB

 

体外研究
(In Vitro)

Bartogenic acid (0.1-100 μM;48 小时) 可在体外抑制人卵巢癌 SKOV-3 细胞的生长,其 IC50 为 15.72 μM。
Bartogenic acid (48 小时) 可强效且选择性地对人皮肤癌细胞 SCC-13 产生细胞毒性 (IC50=7.5 µM),其选择性指数为 4.05。

Cell Viability Assay

Cell Line: human ovarian cancer SKOV-3 cells
Concentration: 0.1 μM; 1 μM; 10 μM; 50 μM; 100 μM
Incubation Time: 48 h
Result: Dose-dependently reduced the viability of SKOV-3 cells, with an IC50 value of 15.72 μM after 48 h of treatment.
Decreased as the concentration of bartogenic acid increased.
体内研究
(In Vivo)

Bartogenic acid (3 mg/kg;静脉注射;每日一次;共 21 天) 可使 SCID 小鼠体内 SKOV-3 卵巢肿瘤的生长抑制 41.47%。
Bartogenic acid (1-4 mg/kg;口服/局部给药;每日;13.5 周) 对 DMBA (MS-Y05966)/巴豆油诱导的 Swiss albino 小鼠皮肤癌具有剂量依赖性化学预防作用,其中 4 mg/kg 口服剂量组的肿瘤发生率最低 (36.1%),且抗氧化标志物水平和皮肤结构接近正常。
Bartogenic acid (2-10 mg/kg;口服;每日一次,共 21 天) 可保护大鼠免受 CFA (MS-E83942) 诱导的原发性和继发性关节炎损伤、体重变化和血液学紊乱。

Animal Model: SCID (female, 5 weeks old, subcutaneous inoculation of SKOV-3 cells to establish a xenograft model)
Dosage: 3 mg/kg
Administration: i.v.; daily; 21 days
Result: Achieved 41.47% tumor growth inhibition (p < 0.001) compared to vehicle controls, with mean tumor volume of 364.70 mm3 on day 21.
Showed no significant reduction in NF-κB H score, viable tumor cell score, fibrosis score, TGF-β1 levels, or MMP9 levels, but significantly increased necrosis score (p < 0.05).
Animal Model: Swiss albino (6-8 weeks old, 23-25 gm, DMBA/Croton oil-induced two-stage skin carcinogenesis)
Dosage: 1 mg/kg; 2 mg/kg; 4 mg/kg
Administration: p.o.; daily; 13.5 weeks; topical; daily; 13.5 weeks
Result: Reduced tumor incidence to 89.3%, with an average of 9.72 tumors per tumor-bearing mouse, mean tumor volume of 124.8 mm3, and mean tumor weight of 1.01 gm at 1 mg/kg oral dose.
Partially restored glutathione (GSH) content and activities of catalase, superoxide dismutase (SOD), and glutathione peroxidase (GSHPx), with mild histopathological improvement at 1 mg/kg oral dose.
Reduced tumor incidence to 52.4%, with an average of 6.34 tumors per tumor-bearing mouse, mean tumor volume of 89.7 mm3, and mean tumor weight of 0.61 gm at 2 mg/kg oral dose.
Significantly reduced skin malondialdehyde (MDA) levels to 125.7 μg/mg protein, restored GSH content to near-normal levels, significantly increased catalase, SOD, and GSHPx activities, and preserved normal skin architecture with only mild epidermal cell invasion at 2 mg/kg oral dose.
Reduced tumor incidence to 36.1%, with an average of 4.19 tumors per tumor-bearing mouse, mean tumor volume of 45.6 mm3, and mean tumor weight of 0.11 gm at 4 mg/kg oral dose.
Significantly reduced skin MDA levels to 104.5 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and preserved fully normal skin architecture with no epidermal thickening or cell invasion at 4 mg/kg oral dose.
Reduced tumor incidence to 48.2%, with an average of 8.21 tumors per tumor-bearing mouse, mean tumor volume of 63.5 mm3, and mean tumor weight of 0.51 gm at 4 mg/kg topical dose.
Reduced skin MDA levels to 141.6 μg/mg protein, restored GSH content and catalase, SOD, and GSHPx activities to near-normal levels, and showed mild to moderate histopathological improvement at 4 mg/kg topical dose.
Animal Model: Wistar rats (either sex, 100-150 g, Complete Freund’s Adjuvant-induced arthritis)
Dosage: 2 mg/kg; 5 mg/kg; 10 mg/kg
Administration: p.o.; daily; 21 days
Result: Reduced primary arthritic lesions to 113% rise in injected paw volume and secondary lesions to 15% rise in non-injected paw volume at 2 mg/kg, 109% rise and 12% rise at 5 mg/kg, and 91% rise and 11% rise at 10 mg/kg (all P <.01).
Resulted in 37 g body weight gain at 2 mg/kg, 36 g gain at 5 mg/kg, and 39 g gain at 10 mg/kg (all P <.01).
Reduced thymus weight to 0.12 g and spleen weight to 0.96 g at 2 mg/kg, 0.12 g and 0.84 g at 5 mg/kg, and 0.085 g and 0.74 g at 10 mg/kg (all thymus weights and 5 mg/kg, 10 mg/kg spleen weights P <.05 or P <.01).
Reduced WBC count to 7.5 ×103/mm3, ESR to 12 mm/h, CRP to 4.4 mg/dL, and RF to 37 IU/mL at 2 mg/kg; increased RBC count to 9 ×106/mm3, reduced WBC count to 7.2 ×103/mm3, increased Hb to 15 mg%, reduced CRP to 2.2 mg/dL, and RF to 33 IU/mL at 5 mg/kg; increased RBC count to 9.8 ×106/mm3, reduced WBC count to 5.6 ×103/mm3, reduced ESR to 11 mm/h, increased Hb to 16 mg%, reduced CRP to 1.4 mg/dL, and RF to 23 IU/mL at 10 mg/kg (all significant vs control, P <.01).
Reduced arthritis score to median 6 (4, 8), flexion pain test score to median 1.5 (1, 2), mobility score to median 1.5 (1, 2), and improved stance score to median 3 (2, 3) at 10 mg/kg (P <.05 or P <.01); 2 mg/kg and 5 mg/kg showed non-significant pain score improvements.
Protected against soft tissue swelling, periarticular bone resorption, bone erosion, and joint space narrowing in the adjuvant-injected paw at 10 mg/kg.

化学信息

分子量 518.68
分子式 C30H46O7
CAS No. 79355-89-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础